tradingkey.logo

Jupiter Neurosciences Inc

JUNS

1.470USD

+0.110+8.09%
Horário de mercado ETCotações atrasadas em 15 min
48.66MValor de mercado
PerdaP/L TTM

Jupiter Neurosciences Inc

1.470

+0.110+8.09%
Mais detalhes de Jupiter Neurosciences Inc Empresa
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Informações da empresa
Código da empresaJUNS
Nome da EmpresaJupiter Neurosciences Inc
Data de listagemDec 03, 2024
CEOMr. Christer Rosen
Número de funcionários4
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço1001 North US HWY 1, Suite 504
CidadePALM BEACH GARDENS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33477
Telefone15614066154
Sitehttps://jupiterneurosciences.com/
Código da empresaJUNS
Data de listagemDec 03, 2024
CEOMr. Christer Rosen
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Julie Kampf
Ms. Julie Kampf
Director
Director
--
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.55M
+0.03%
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
+0.67%
Ms. Allison W. Brady
Ms. Allison W. Brady
Director
Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Director
Director
10.78K
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Director
Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 9 de jul
Atualizado em: qua, 9 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Investidores
Investidores
Proporção
Rosen (Christer)
34.90%
Wahlestedt (Claes M.D., Ph.D.)
8.47%
Hayward (Marshall A Ph.D.)
7.19%
Brothers (Shaun P.)
5.13%
Rosen (Alexander Gustaf Erik)
1.37%
Other
42.94%
Tipos de investidores
Investidores
Proporção
Individual Investor
57.70%
Investment Advisor
0.49%
Research Firm
0.34%
Hedge Fund
0.31%
Investment Advisor/Hedge Fund
0.03%
Other
41.13%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
18
19.49M
58.89%
+1.54M
2025Q1
16
18.33M
55.39%
+383.02K
2024Q4
9
17.92M
54.13%
+14.81M
2024Q3
6
5.31M
79.52%
--
2024Q2
10
5.31M
79.52%
-11.63K
2024Q1
10
5.31M
79.52%
-11.63K
2023Q4
10
5.31M
79.52%
-11.63K
2023Q3
10
5.31M
79.52%
-11.63K
2023Q2
10
5.31M
79.52%
-11.63K
2023Q1
11
5.31M
79.57%
-15.77K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Rosen (Christer)
11.55M
34.89%
+981.28K
+9.29%
Jun 30, 2025
Wahlestedt (Claes M.D., Ph.D.)
2.80M
8.47%
--
--
Mar 12, 2025
Hayward (Marshall A Ph.D.)
2.38M
7.19%
--
--
Mar 12, 2025
Brothers (Shaun P.)
1.70M
5.13%
--
--
Mar 12, 2025
Rosen (Alexander Gustaf Erik)
452.86K
1.37%
--
--
Mar 12, 2025
UBS Financial Services, Inc.
135.64K
0.41%
+135.62K
+542460.00%
Mar 31, 2025
Silva (Alison D)
112.03K
0.34%
+112.03K
--
Jun 30, 2025
Citi Investment Research (US)
111.98K
0.34%
+107.49K
+2393.92%
Mar 31, 2025
Two Sigma Investments, LP
90.19K
0.27%
+90.19K
--
Mar 31, 2025
Elmasri (Saleem C)
66.29K
0.2%
+66.29K
--
Jun 02, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI